Germline mutations associated with RMS
p53 BWS (11p15 LOH) Costello (HRAS) Noonan (Ras-Mapk) NF-1 Gorlin (PTCH1) Dicer1
Name translocation seen in alveolar RMS
Pax3-FOXO1 t(2;13)
Pax7-FOXO1 t(1;13)
RMS immunohistochemical staining to differentiate from other SRBCT
myoD
myogenin
desmin
muscle specific actin
Favourable sites for IRS staging
Who can avoid bone marrow?
- all NRSTS
RMS risk group classification
Low risk:
Int risk:
High risk:
- met ERMS or ARMS
Role of radiation in RMS
Prognostic factors in RMS
Chemo responsive NRSTS
synovial sarcoma - (X; 18) translocation
undifferentiated sarcoma
infantile fibrosarcoma - (12;15) translocation
NRSTS chemo non-responsive
MPNST
Leiomyosarcoma
Aveloar soft part sarcoma
Epitheloid sarcoma
Translocations for:
Prognosis for RMS
Low risk 85%
Int risk 50-75%
High risk <20%
Who needs LN exploration in RMS
Chemo used for NRSTS
Ifos/Doxo
ARST 0331 - low risk protocol
ARST 0531 - int. risk protocol
VAC vs VAC/VI - same outcomes
VAC/VI had:
Long term toxicity of therapy
Infertility - related to cyclo and pelvic rads
SMA - 2-3% at 30 yrs related to p53 and rads
Bone growth/atrophy - rads
Syndromes associated with NRSTS
Prognostic factors in NRSTS
NRSTS associated with HIV/immunosuppression
leiomyosarcoma
NRSTS likely to spread to LNs
Epithelioid sarcoma and clear cell sarcoma
NRSTS most common in < 1yo
Infantile fibrosarcoma and infantile hemangioperiocytoma
Osteo:
cytogenetics: chromothripsis, supernumary ring chromosome (parosteal)
Molecular: Rb, p53, RECQL4 (rothmund thompson syndrome)
Prognostic factors in Osteosarcoma